Forward cardiac output measurement with first-pass technique using 99mTc-labeled myocardial perfusion imaging agents.
The aim of this study was to develop and validate a new first-pass method for the measurement of forward cardiac output (CO) using 99mTc-labeled myocardial perfusion imaging agents.


METHODS
In protocol 1, to test the new method for measuring CO, the conventional method and the new method for CO measurement were performed in 1 d in 57 patients (32 men, 25 women; age 68 +/- 11 y). In the conventional method, radionuclide angiography (1 frame/s) with in vivo 99mTc labeling (110 MBq) of red blood cells was performed for 2 min in the left anterior oblique projection. Five minutes later, a 1-min equilibrium image was obtained, and a blood sample was taken for calculation of the distribution volume. To obtain data for the new method, further radionuclide angiography (1 frame/sec) with 99mTc labeling (600-740 MBq) of red blood cells was then performed in the anterior projection. CO was calculated using the following equation: CO = Cmax x V(LV)/integral of f(t)dt, where Cmax is the background-corrected peak count of the whole thorax during angiography, integral of f(t)dt is the area under the gamma variate-fitted left ventricular (LV) time-activity curve after background correction and V(LV) is the LV volume obtained by the area length method applied to the radionuclide angiography and myocardial tomography. In protocol 2, to evaluate the new method, 24 patients (16 men, 8 women; age 71 +/- 9.2 y) underwent radionuclide angiography with 99mTc-tetrofosmin (600-740 MBq), and the measured CO was compared with the CO obtained by the conventional method with 99mTc-labeled red blood cells.


RESULTS
In protocol 1, good correlation was observed between the CO by the new method (Y) and the CO by the conventional method (X): Y = 1.0X + 57 mL/min and r = 0.95. There was good agreement between the two methods (mean difference -56 +/- 381 mL/min). Inter- and intraobserver correlation coefficients were 0.96 and 0.98, respectively. In protocol 2, the CO by the new method using 99mTc-tetrofosmin (Y) showed a good correlation with the CO by the conventional method (X): Y = 0.90X + 453 mL/min and r = 0.93. Good agreement between the two methods was observed (mean difference 73 +/- 390 mL/min). Inter- and intraobserver correlation coefficients were 0.95 and 0.98, respectively.


CONCLUSIONS
This new method permits accurate forward CO measurement using the first-pass data with 99mTc-terofosmin, which is applicable to other 99mTc-labeled myocardial perfusion imaging agents.
Taki
J
J
Department of Nuclear Medicine, Kanazawa University School of Medicine, Japan.
Muramori
A
A
Kinuya
S
S
Nakajima
K
K
Matsunari
I
I
Miyazaki
Y
Y
Murata
Y
Y
Tonami
N
N
D000368:Aged; D002302:Cardiac Output; D004912:Erythrocytes; D005260:Female; D006801:Humans; D008297:Male; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D013667:Technetium; D017256:Technetium Tc 99m Sestamibi; D015899:Tomography, Emission-Computed, Single-Photon; D015646:Ventriculography, First-Pass
D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C078700:technetium tc-99m tetrofosmin; D013667:Technetium; D017256:Technetium Tc 99m Sestamibi